Literature DB >> 9505884

Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study.

C P Bearcroft1, D Perrett, M J Farthing.   

Abstract

BACKGROUND: Increased concentrations of 5-hydroxytryptamine (5-HT) can be detected in the systemic circulation after a meal and may be involved in the physiological control of gastrointestinal motility. Abnormalities of 5-HT release after a meal might explain some of the postprandial symptoms associated with the irritable bowel syndrome (IBS). AIM: To investigate the effect of a standard meal on plasma 5-HT and urinary 5-hydroxyindole acetic acid (5-HIAA) concentrations in patients with diarrhoea predominant IBS and in healthy volunteers.
METHODS: After an overnight fast, six volunteers and five patients with IBS were given a carbohydrate-rich meal. Blood and urine samples were taken before and for four hours after the meal. Platelet-poor plasma 5-HT and urinary 5-HIAA were analysed by reversed phase high performance liquid chromatography with fluorometric detection. 5-HIAA was expressed as a ratio with urinary creatinine concentration, which was measured by spectrophotometry.
RESULTS: During the four hour postprandial period, 5-HT concentrations were significantly higher in patients with IBS than in healthy volunteers at 0.5 hours (p < 0.05), 2 hours (p < 0.05) and 2.5 hours (p < 0.05). 5-HT was not detected in the plasma in the fasting state in patients or volunteers. Median peak 5-HT in patients with IBS (359 (198-796) nmol/l) was significantly greater than volunteers (83 (7-190)) (p < 0.05). "Area under the curve" for 5-HT detection was greater for patients with IBS (317 (138-771)) than for healthy volunteers (51 (4-129); p < 0.05). The duration of the 5-HT peak was significantly longer in patients with IBS (3 (1-3) hours) than in the healthy volunteers (1 (1-1) hours; p < 0.01). Postprandial urinary median 5-HIAA values in controls (5.6 (5.5-5.8) mumol/mmol creatinine) and patients with IBS (3.0 (2.5-6.8) mumol/mmol creatinine) were not significantly different from preprandial values (controls: 5.9 (5.5-6.6) mumol/mmol creatinine; patients with IBS: (6.2 (2.4-9.3) mumol/mmol creatinine).
CONCLUSION: These findings indicate that there may be a difference in the way that 5-HT is released in patients with diarrhoea predominant IBS, and could suggest a possible role for 5-HT in the postprandial symptoms of these patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9505884      PMCID: PMC1726971          DOI: 10.1136/gut.42.1.42

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  41 in total

1.  Enterochromaffin cells in macrophages in ulcerative colitis and irritable colon.

Authors:  A Ahonen; K Kyösola; O Penttilä
Journal:  Ann Clin Res       Date:  1976-02

2.  Effects of intraluminal perfusion with serotonin on jejunal motility.

Authors:  H G Märtensson; M J Zinner; B M Jaffe
Journal:  Dig Dis Sci       Date:  1986-08       Impact factor: 3.199

3.  Psychological characteristics of patients with the irritable bowel syndrome.

Authors:  R L Palmer; E Stonehill; A H Crisp; S L Waller; J J Misiewicz
Journal:  Postgrad Med J       Date:  1974-07       Impact factor: 2.401

4.  Validation and application of a radioimmunoassay for serotonin.

Authors:  J M Kellum; B M Jaffe
Journal:  Gastroenterology       Date:  1976-04       Impact factor: 22.682

5.  GR 38032F (ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man.

Authors:  N J Talley; S F Phillips; A Haddad; L J Miller; C Twomey; A R Zinsmeister; R L MacCarty; A Ciociola
Journal:  Dig Dis Sci       Date:  1990-04       Impact factor: 3.199

6.  Abnormal illness attitudes in patients with irritable bowel syndrome.

Authors:  J Gomborone; P Dewsnap; G Libby; M Farthing
Journal:  J Psychosom Res       Date:  1995-02       Impact factor: 3.006

7.  Participation of serotonin on early and delayed emesis induced by initial and subsequent cycles of cisplatinum-based chemotherapy: effects of antiemetics.

Authors:  L X Cubeddu; I S Hoffmann
Journal:  J Clin Pharmacol       Date:  1993-08       Impact factor: 3.126

8.  Simplified determination of serotonin in plasma by liquid chromatography with electrochemical detection.

Authors:  P C Tagari; D J Boullin; C L Davies
Journal:  Clin Chem       Date:  1984-01       Impact factor: 8.327

9.  Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5 HT3-receptor antagonist, in patients with irritable bowel syndrome.

Authors:  A Prior; N W Read
Journal:  Aliment Pharmacol Ther       Date:  1993-04       Impact factor: 8.171

10.  Blood serotonin levels in adults, autistic and non-autistic children--with a comparison of different methodologies.

Authors:  N R Badcock; J G Spence; L M Stern
Journal:  Ann Clin Biochem       Date:  1987-11       Impact factor: 2.057

View more
  77 in total

Review 1.  Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome.

Authors:  Michael Camilleri; David A Katzka
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-03-08       Impact factor: 4.052

2.  Of actors, bolting horses, and drops in oceans!

Authors:  F Cremonini; M Camilleri
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

3.  Characteristics of 5-hydroxytryptamine receptors involved in contraction of feline ileal longitudinal smooth muscle.

Authors:  Yiyi Wang; Sun Young Park; Kyung Hoon Oh; Youngsil Min; Yun-Jeong Lee; Seok-Yong Lee; Uy Dong Sohn
Journal:  Korean J Physiol Pharmacol       Date:  2011-10-31       Impact factor: 2.016

4.  A clinicopathological study of serotonin of sigmoid colon mucosa in association with chronic symptoms in uncomplicated diverticulosis.

Authors:  S Jeyarajah; N Akbar; J Moorhead; A Haji; S Banerjee; S Papagrigoriadis
Journal:  Int J Colorectal Dis       Date:  2012-06-29       Impact factor: 2.571

5.  Associations of tryptophan hydroxylase gene polymorphisms with irritable bowel syndrome.

Authors:  S Jun; R Kohen; K C Cain; M E Jarrett; M M Heitkemper
Journal:  Neurogastroenterol Motil       Date:  2010-11-12       Impact factor: 3.598

6.  Opposite effects of serotonin and interferon-alpha on the membrane potential and function of human natural killer cells.

Authors:  Tibor Oláh; Imre Ocsovszki; Yvette Mándi; Rozália Pusztai; Márta Bakay; Elisabeth Balint
Journal:  In Vitro Cell Dev Biol Anim       Date:  2005 May-Jun       Impact factor: 2.416

7.  Immune activation and gut microbes in irritable bowel syndrome.

Authors:  Khaldun Al-Khatib; Henry C Lin
Journal:  Gut Liver       Date:  2009-03-31       Impact factor: 4.519

8.  Irritable Bowel Syndrome: Bacterial Overgrowth--What's Known and What to Do.

Authors:  Mark Pimentel; Sheila Lezcano
Journal:  Curr Treat Options Gastroenterol       Date:  2007-08

9.  Portal 5-hydroxytryptophan infusion enhances glucose disposal in conscious dogs.

Authors:  Mary Courtney Moore; Kazuhiro Kimura; Haruki Shibata; Tsutomu Honjoh; Masayuki Saito; Carrie A Everett; Marta S Smith; Alan D Cherrington
Journal:  Am J Physiol Endocrinol Metab       Date:  2005-03-08       Impact factor: 4.310

Review 10.  New insights into the psychosocial aspects of irritable bowel syndrome.

Authors:  Richard Lea; Peter J Whorwell
Journal:  Curr Gastroenterol Rep       Date:  2003-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.